1049 related articles for article (PubMed ID: 23583249)
1. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
[TBL] [Abstract][Full Text] [Related]
3. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial.
Reddy VY; Doshi SK; Sievert H; Buchbinder M; Neuzil P; Huber K; Halperin JL; Holmes D;
Circulation; 2013 Feb; 127(6):720-9. PubMed ID: 23325525
[TBL] [Abstract][Full Text] [Related]
5. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
[TBL] [Abstract][Full Text] [Related]
6. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.
Reddy VY; Holmes D; Doshi SK; Neuzil P; Kar S
Circulation; 2011 Feb; 123(4):417-24. PubMed ID: 21242484
[TBL] [Abstract][Full Text] [Related]
7. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
[TBL] [Abstract][Full Text] [Related]
9. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation.
Alli O; Doshi S; Kar S; Reddy V; Sievert H; Mullin C; Swarup V; Whisenant B; Holmes D
J Am Coll Cardiol; 2013 Apr; 61(17):1790-8. PubMed ID: 23500276
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous WATCHMAN Left Atrial Appendage Closure for Japanese Patients With Nonvalvular Atrial Fibrillation at Increased Risk of Thromboembolism - First Results From the SALUTE Trial.
Aonuma K; Yamasaki H; Nakamura M; Ootomo T; Takayama M; Ando K; Hirao K; Morino Y; Hayashida K; Kusano K; Main ML; Saito S
Circ J; 2018 Nov; 82(12):2946-2953. PubMed ID: 30305484
[TBL] [Abstract][Full Text] [Related]
12. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.
Holmes DR; Doshi SK; Kar S; Price MJ; Sanchez JM; Sievert H; Valderrabano M; Reddy VY
J Am Coll Cardiol; 2015 Jun; 65(24):2614-2623. PubMed ID: 26088300
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Mazzone P; Foley D; Grygier M; Sievert H; De Potter T; Vireca E; Stein K; Bergmann MW;
Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006841. PubMed ID: 30939908
[TBL] [Abstract][Full Text] [Related]
15. Catheter ablation in combination with left atrial appendage closure for atrial fibrillation.
Swaans MJ; Alipour A; Rensing BJ; Post MC; Boersma LV
J Vis Exp; 2013 Feb; (72):e3818. PubMed ID: 23486416
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Foley D; Sievert H; Mazzone P; De Potter T; Vireca E; Stein K; Bergmann MW;
Heart Rhythm; 2017 Sep; 14(9):1302-1308. PubMed ID: 28577840
[TBL] [Abstract][Full Text] [Related]
18. Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure.
Saw J; Fahmy P; Azzalini L; Marquis JF; Hibbert B; Morillo C; Carrizo A; Ibrahim R
J Cardiovasc Electrophysiol; 2017 Apr; 28(4):396-401. PubMed ID: 28128883
[TBL] [Abstract][Full Text] [Related]
19. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
Freeman JV; Hutton DW; Barnes GD; Zhu RP; Owens DK; Garber AM; Go AS; Hlatky MA; Heidenreich PA; Wang PJ; Al-Ahmad A; Turakhia MP
Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27307517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
